AFN50 is an mRNA-based in vivo CAR-T program designed to directly program and activate T cells in vivo for the selective elimination of pathogenic immune cells in autoimmune diseases. The program is currently being evaluated in investigator-initiated trials (IIT).

AFN56 is a first-in-class in vivo Tol-APC program that directly generates tolerogenic antigen-presenting cells in vivo to induce immune tolerance and suppress aberrant immune responses in autoimmune diseases. The program is currently in IIT studies.

AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.

AFN03 is a therapeutic mRNA-based nucleic acid program for HPV16/18-related diseases. The program is in Phase II for HPV16/18-associated precancerous lesions and Phase I clinical trials for cervical cancer, head and neck cancer, and other solid tumors.

AFN18 is an mRNA immunotherapy technology based on tumor neoantigens, used for the treatment of solid tumors. It is currently in the exploratory clinical research stage and has undergone safety and preliminary efficacy evaluations in digestive system tumors such as colorectal cancer.

AFN02 is a prophylactic mRNA vaccine targeting respiratory syncytial virus (RSV) and is currently in Phase II clinical development. It represents one of the most advanced and potentially first-in-class mRNA RSV vaccine programs in China.

AFN12 is an mRNA vaccine candidate for the prevention of Herpes Zoster and is currently in Phase I clinical development, further expanding the company’s portfolio in prophylactic vaccines.